Anika Therapeutics (ANIK) EPS (Weighted Average and Diluted): 2010-2025
Historic EPS (Weighted Average and Diluted) for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to -$0.22.
- Anika Therapeutics' EPS (Weighted Average and Diluted) rose 89.16% to -$0.22 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 65.05%. This contributed to the annual value of -$3.83 for FY2024, which is 32.09% up from last year.
- Latest data reveals that Anika Therapeutics reported EPS (Weighted Average and Diluted) of -$0.22 as of Q3 2025, which was up 33.33% from -$0.33 recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' EPS (Weighted Average and Diluted) registered a high of $0.45 during Q2 2021, and its lowest value of -$4.30 during Q4 2023.
- Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.34 (2025), whereas its average is -$0.96.
- Per our database at Business Quant, Anika Therapeutics' EPS (Weighted Average and Diluted) soared by 183.33% in 2021 and then crashed by 1,164.71% in 2023.
- Anika Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.40 in 2021, then grew by 15.00% to -$0.34 in 2022, then plummeted by 1,164.71% to -$4.30 in 2023, then soared by 65.35% to -$1.49 in 2024, then soared by 89.16% to -$0.22 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.22 in Q3 2025, compared to -$0.33 in Q2 2025 and -$0.34 in Q1 2025.